IO Biotech, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for IO Biotech, Inc. (IOBTQ), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are IOBTQ insiders buying or selling?
IO Biotech, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since November 2021, Trabud has recorded 19 Form 4 filings for IOBTQ: 16 buys ($74.0M) and 3 sells ($1.9M).
Source: SEC EDGAR Form 4
Key Statistics (November 2021 – Jun 2, 2025)
Total Form 4 filings
19
SEC EDGAR
Insider filers
13
Insider buys (16)
$74.0M
Insider sells (3)
$1.9M
Insider sentiment
Net buyingNet insider flow of $72.2M in net buying since November 2021.
Recent IOBTQ insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 2, 2025 | Heidi Hunter | Director | Purchase | 15.0K | $1.39 | $20.9K | SEC ↗ |
| Dec 26, 2024 | Qasim Iftikhar Ahmad | Chief Medical Officer | Purchase | 31.4K | $0.85 | $26.6K | SEC ↗ |
| Dec 23, 2024 | Mai-Britt Zocca | Chief Executive Officer | Purchase | 12.5K | $0.81 | $10.1K | SEC ↗ |
| Dec 23, 2024 | Amy Sullivan | Chief Financial Officer | Purchase | 10.3K | $0.83 | $8.5K | SEC ↗ |
| Dec 23, 2024 | Devin Whittemore Smith | General Counsel | Purchase | 12.0K | $0.81 | $9.7K | SEC ↗ |
| Jul 27, 2024 | Novo Holdings A/S | 10% Owner | Sale | 75.0K | $1.32 | $99.1K | SEC ↗ |
| May 15, 2024 | Novo Holdings A/S | 10% Owner | Sale | 658.8K | $1.22 | $802.5K | SEC ↗ |
| Feb 14, 2024 | Novo Holdings A/S | 10% Owner | Sale | 658.8K | $1.50 | $988.4K | SEC ↗ |
| Nov 24, 2023 | Brian Burkavage | Chief Accounting Officer | Purchase | 10.0K | $1.01 | $10.1K | SEC ↗ |
| Aug 11, 2023 | Novo Holdings A/S | 10% Owner | Purchase | 2.5M | $2.03 | $5.0M | SEC ↗ |
| Aug 10, 2023 | Vivo Capital IX, LLC | 10% Owner | Purchase | 3.2M | $1.90 | $6.0M | SEC ↗ |
| Mar 20, 2023 | Amy Sullivan | Chief Financial Officer | Purchase | 25.0K | $2.32 | $58.0K | SEC ↗ |
| Nov 12, 2021 | HBM Healthcare Investments (Cayman) Ltd. | 10% Owner | Purchase | 325.0K | $14.00 | $4.5M | SEC ↗ |
| Nov 12, 2021 | Vanessa Malier | Director | Purchase | 325.0K | $14.00 | $4.5M | SEC ↗ |
| Nov 12, 2021 | Vivo Capital IX, LLC | 10% Owner | Purchase | 650.0K | $14.00 | $9.1M | SEC ↗ |
| Nov 12, 2021 | Claus A. Andersson | Director | Purchase | 75.0K | $14.00 | $1.1M | SEC ↗ |
| Nov 12, 2021 | Lundbeckfond Invest A/S | 10% Owner | Purchase | 2.1M | $14.00 | $30.0M | SEC ↗ |
| Nov 12, 2021 | Jack Nielsen | Director | Purchase | 650.0K | $14.00 | $9.1M | SEC ↗ |
| Nov 11, 2021 | Novo Holdings A/S | 10% Owner | Purchase | 325.0K | $14.00 | $4.5M | SEC ↗ |
Showing the 19 most recent of 19 Form 4 filings for IO Biotech, Inc..
Most active IOBTQ insiders
- Novo Holdings A/S5 filings
- Amy Sullivan2 filings
- Vivo Capital IX, LLC2 filings
- Brian Burkavage1 filing
- Claus A. Andersson1 filing
Ask anything about IOBTQ insider activity
Use Trabud's AI agent to query IO Biotech, Inc.'s Form 4 history in plain English — "Show me IOBTQ CEO purchases this year" or compare it against any other ticker.
Open the AI agentIOBTQ insider trading FAQ
Are IO Biotech, Inc. insiders buying or selling?
IO Biotech, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since November 2021, Trabud has recorded 19 Form 4 filings for IOBTQ: 16 buys ($74.0M) and 3 sells ($1.9M). Over the full record that is net buying of $72.2M.
How many insiders trade IOBTQ stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for IO Biotech, Inc.. The most recent filing was accepted on Jun 2, 2025.
Where does Trabud get IOBTQ insider trading data?
All IOBTQ insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.